Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(37.5%)

Phase 2

2(25.0%)

Phase 4

2(25.0%)

Phase 1

1(12.5%)

8Total

N/A(3)

Phase 2(2)

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05644145Not ApplicableActive Not Recruiting

Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in Argentina

Role: lead

NCT03775551Not ApplicableCompleted

Counter-referral System Improvement Collaborative

Role: collaborator

NCT03924570Not ApplicableCompleted

Reducing Adverse Events in Pediatric Intensive Care Units in Argentina

Role: collaborator

NCT04894721Phase 2Completed

Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC)

Role: lead

NCT04988048Phase 2Unknown

Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina

Role: lead

NCT04784481Phase 1Completed

Ivermectin Reproposing for Mild Stage COVID-19 Outpatients

Role: lead

NCT04831632Unknown

Diagnostic Performance Assessment of Qualitative Ifobt and Quantitative Ifobt for Advanced Neoplastic

Role: collaborator

NCT03368495Phase 4Completed

Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines

Role: collaborator

NCT02280174Phase 4Unknown

Effect of Linagliptin on TRL Metabolism

Role: lead

All 9 trials loaded